Back to mobile site

More on NRXP

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/16/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

NRx Pharmaceuticals (NQ:NRXP)
Delayed: 3.42 -0.05 (1.44%)
Prev. Close $3.47  
Open$3.48 
52 Wk High$ 
52 Wk Low$ 
Day High$3.52 
Day Low$3.40 
P/E N/A  
EPS$ 
Volume191,724 

Friends, Peers and Foes (?): DVLT, RDZN, MDCX, VTIX, SNYR (more...)

Sep 8, 2026 07:00 AM NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 26, 2026 06:43 AM H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
Aug 17, 2026 08:00 AM Form 8-K NRX Pharmaceuticals, For: Aug 17
Aug 17, 2026 07:00 AM NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
Aug 14, 2026 04:37 PM Form 10-Q NRX Pharmaceuticals, For: Jun 30
Aug 10, 2026 06:50 AM H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
Aug 7, 2026 04:01 PM NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
Aug 7, 2026 07:01 AM FDA completes first-cycle review of NRx ketamine ANDA with packaging query
Aug 7, 2026 07:01 AM Form 8-K NRX Pharmaceuticals, For: Aug 07
Aug 7, 2026 07:00 AM FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
View All Articles

Entities mentioned with NRXP

View All Entities